Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Legha

Showing results (161-170 of 179) with videos related to

Pageof 18
Sort By:
Annals of Internal Medicine|December 1, 1979
Complete remissions in metastatic breast cancer treated with combination drug therapyS S Legha, A U Buzdar, T L Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1987
Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized studyG N Hortobagyi, G P Bodey, A U Buzdar, et al.
Cancer Treatment Reports|January 1, 1980
Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccineG N Hortobagyi, H Y Yap, C L Wiseman, et al.
In Vivo (Athens, Greece)|November 1, 1991
Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapiesK Itoh, C M Balch, J L Murray, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 14, 2006
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanomaE Bajetta, M Del Vecchio, P Nova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1995
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapyA Y Bedikian, G R Weiss, S S Legha, et al.
Melanoma Research|June 4, 1998
DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanomaA C Buzaid, F Ali-Osman, N Akande, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|October 1, 1991
Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCCK Hayakawa, M A Salmeron, D R Parkinson, et al.
Cancer|June 15, 1981
Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimensA U Buzdar, S S Legha, G N Hortobagyi, et al.
Cancer Treatment Reports|February 1, 1982
High-dose AMSA and bone marrow rescue in patients with solid tumorsA R Zander, G Spitzer, S Legha, et al.
Pageof 18

Showing results (161-170 of 179) with videos related to

Sort By:
Pageof 18
Annals of Internal Medicine|December 1, 1979
Complete remissions in metastatic breast cancer treated with combination drug therapyS S Legha, A U Buzdar, T L Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1987
Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized studyG N Hortobagyi, G P Bodey, A U Buzdar, et al.
Cancer Treatment Reports|January 1, 1980
Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccineG N Hortobagyi, H Y Yap, C L Wiseman, et al.
In Vivo (Athens, Greece)|November 1, 1991
Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapiesK Itoh, C M Balch, J L Murray, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 14, 2006
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanomaE Bajetta, M Del Vecchio, P Nova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1995
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapyA Y Bedikian, G R Weiss, S S Legha, et al.
Melanoma Research|June 4, 1998
DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanomaA C Buzaid, F Ali-Osman, N Akande, et al.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy|October 1, 1991
Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCCK Hayakawa, M A Salmeron, D R Parkinson, et al.
Cancer|June 15, 1981
Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimensA U Buzdar, S S Legha, G N Hortobagyi, et al.
Cancer Treatment Reports|February 1, 1982
High-dose AMSA and bone marrow rescue in patients with solid tumorsA R Zander, G Spitzer, S Legha, et al.
Pageof 18